OmniAb, Inc. (NASDAQ:OABI) CEO Sells $51,387.52 in Stock

OmniAb, Inc. (NASDAQ:OABI) CEO Matthew W. Foehr sold 13,964 shares of the firm’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $3.68, for a total transaction of $51,387.52. Following the sale, the chief executive officer now directly owns 3,798,682 shares of the company’s stock, valued at $13,979,149.76. This trade represents a 0.37 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

OmniAb Trading Up 5.7 %

Shares of OABI stock opened at $3.88 on Friday. OmniAb, Inc. has a 12-month low of $3.10 and a 12-month high of $6.55. The firm’s 50 day moving average is $3.49 and its 200 day moving average is $3.91. The stock has a market capitalization of $547.93 million, a P/E ratio of -6.26 and a beta of -0.12.

Institutional Investors Weigh In On OmniAb

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Hsbc Holdings PLC purchased a new stake in OmniAb in the fourth quarter worth approximately $38,000. Choreo LLC purchased a new stake in OmniAb in the fourth quarter worth approximately $41,000. Rangeley Capital LLC purchased a new position in shares of OmniAb during the 4th quarter worth $41,000. CWC Advisors LLC. bought a new stake in shares of OmniAb during the 3rd quarter valued at $54,000. Finally, KLP Kapitalforvaltning AS bought a new stake in shares of OmniAb during the 4th quarter valued at $49,000. Hedge funds and other institutional investors own 72.08% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on OABI. HC Wainwright reissued a “buy” rating and set a $11.00 price target on shares of OmniAb in a research report on Thursday, November 14th. Benchmark reissued a “buy” rating and set a $8.00 price target on shares of OmniAb in a research report on Thursday, November 14th.

OmniAb Company Profile

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.